Sera Prognostics, Inc.
NASDAQ:SERAMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $74.11M
- Beta
- 0.94
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.06M
SERA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Sera Prognostics, Inc.NASDAQ: SERA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $8K (cash outflow) rose 166.7% year over year, ahead of the +86.5% change in trailing-twelve-month capital expenditures. Sequentially, it fell 97.6% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Capital expenditures amounted to 896.3% of revenue in FY2025, down 533.6 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +166.7% holds above the trailing-twelve-month pace of +86.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (726K) USD
- Year-over-year change
- +34.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (726K) | +34.1% |
| FY2024 | 2024-12-31 | (1.1M) | -760.2% |
| FY2023 | 2023-12-31 | (128K) | +83.8% |
| FY2022 | 2022-12-31 | (791K) | +39.3% |
| FY2021 | 2021-12-31 | (1.3M) | — |
Capital Expenditures vs competitors
How SERA compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +86.5% is the 4th highest of 8, against a peer median of +50.8%.
- Capital expenditures amounts to 1282.5% of revenue for SERA, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $186.01M USD | +82077.2% | — | 46866.7% | |
| LTM Mar 2026 | $1.12M USD | +50.8% | +3.3% | 2.0% | |
| LTM Mar 2026 | $925K USD | -15.8% | -49.9% | 2.7% | |
| LTM Mar 2026 | $731K USD | +86.5% | -2.8% | 1282.5% | |
| LTM Mar 2026 | $319K USD | -54.6% | -39.9% | 6.2% | |
| LTM Mar 2026 | $221K USD | +380.4% | -44.0% | 2.9% | |
| LTM Mar 2026 | $82.26K USD | — | -31.0% | — | |
| LTM Mar 2026 | CA$15.65K CAD | -91.9% | -46.9% | — | |
| LTM Mar 2026 | $0 USD | +100.0% | — | — | |
| Peer median (excluding SERA) | — | +50.8% | -41.9% | 2.9% | |
Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Depreciation & Amortization | 659K | 756K | 900K | 833K | 940K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.13M | 5.06M | 5.27M | 7.01M | 5.11M |
| Change in Working Capital | (44K) | 3.55M | 3.52M | 11.28M | (546K) |
| Accounts Receivables | (3.14M) | (2.97M) | (5.36M) | 11.42M | 22K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 603K | 352K | (442K) | 455K | (1.01M) |
| Other Working Capital | 2.49M | 6.17M | 9.32M | (597K) | 441K |
| Other Non-Cash Items | (372K) | 213K | (638K) | (412K) | 801K |
| Operating Cash Flow | (31.64M) | (34.61M) | (27.19M) | (14.19M) | (25.62M) |
| Capital Expenditures | (1.3M) | (791K) | (128K) | (1.1M) | (726K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.06M) | (48.07M) | (54.14M) | (35.83M) | (87.61M) |
| Sales of Investments | 800K | 54.4M | 54.4M | 48.68M | 59.84M |
| Other Investing Activities | 0 | 16K | 311K | (1.05M) | 0 |
| Investing Cash Flow | (82.56M) | 5.55M | 438K | 11.74M | (28.5M) |
| Debt Repayment | (7.66M) | (303K) | (466K) | (440K) | (194K) |
| Common Stock Issued | 66.61M | 0 | 0 | 0 | 54.22M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.66M | 308K | 1.22M | 3.05M | 0 |
| Financing Cash Flow | 159.59M | 5K | 752K | 2.61M | 54.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.4M | (29.05M) | (26M) | 163K | (99K) |
| Free Cash Flow | (32.94M) | (35.4M) | (27.32M) | (15.29M) | (26.35M) |
Sera Prognostics, Inc.
NASDAQ:SERA
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.